Maria Monica Gramatges

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2848479/publications.pdf

Version: 2024-02-01

64 papers 909 citations

567281 15 h-index 477307 29 g-index

64 all docs

64
docs citations

64 times ranked 2112 citing authors

#	Article	IF	CITATIONS
1	Germline Mutations in Shelterin Complex Genes Are Associated With Familial Glioma. Journal of the National Cancer Institute, 2015, 107, 384.	6.3	172
2	Premature Physiologic Aging as a Paradigm for Understanding Increased Risk of Adverse Health Across the Lifespan of Survivors of Childhood Cancer. Journal of Clinical Oncology, 2018, 36, 2206-2215.	1.6	99
3	Longer Relative Telomere Length in Blood from Women with Sporadic and Familial Breast Cancer Compared with Healthy Controls. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 605-613.	2.5	80
4	Short telomeres: from dyskeratosis congenita to sporadic aplastic anemia and malignancy. Translational Research, 2013, 162, 353-363.	5.0	73
5	T Cells Expressing Constitutively Active Akt Resist Multiple Tumor-associated Inhibitory Mechanisms. Molecular Therapy, 2010, 18, 2006-2017.	8.2	64
6	Prevalence and Predictors of Frailty in Childhood Cancer Survivors and Siblings: A Report From the Childhood Cancer Survivor Study. Journal of Clinical Oncology, 2020, 38, 232-247.	1.6	55
7	The Adolescent and Young Adult with Cancer: State of the Art Acute Leukemias. Current Oncology Reports, 2013, 15, 317-324.	4.0	31
8	Telomere Content and Risk of Second Malignant Neoplasm in Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study. Clinical Cancer Research, 2014, 20, 904-911.	7.0	31
9	Neonatal alloimmune thrombocytopenia and neutropenia associated with maternal human leukocyte antigen antibodies. Pediatric Blood and Cancer, 2009, 53, 97-99.	1.5	29
10	A homozygous telomerase T-motif variant resulting in markedly reduced repeat addition processivity in siblings with Hoyeraal Hreidarsson syndrome. Blood, 2013, 121, 3586-3593.	1.4	28
11	An overview of disparities in childhood cancer: Report on the Inaugural Symposium on Childhood Cancer Health Disparities, Houston, Texas, 2016. Pediatric Hematology and Oncology, 2018, 35, 95-110.	0.8	25
12	Somatic mutations in children with GATA2-associated myelodysplastic syndrome who lack other features of GATA2 deficiency. Blood Advances, 2017, 1, 443-448.	5.2	23
13	Absolute lymphocyte counts refine minimal residual diseaseâ€based risk stratification in childhood acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2012, 59, 468-474.	1.5	20
14	Genetic variation in POT1 and risk of thyroid subsequent malignant neoplasm: A report from the Childhood Cancer Survivor Study. PLoS ONE, 2020, 15, e0228887.	2,5	18
15	Shorter Remission Telomere Length Predicts Delayed Neutrophil Recovery After Acute Myeloid Leukemia Therapy: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2016, 34, 3766-3772.	1.6	17
16	The relationship between chronic health conditions and cognitive deficits in children, adolescents, and young adults with down syndrome: A systematic review. PLoS ONE, 2020, 15, e0239040.	2.5	14
17	Survival disparities for second primary malignancies diagnosed among childhood cancer survivors: A populationâ€based assessment. Cancer, 2019, 125, 3623-3630.	4.1	11
18	Ethnic disparities relative to disease features and outcomes in children with acute myeloid leukemia. Pediatric Blood and Cancer, 2017, 64, e26487.	1.5	10

#	Article	IF	CITATIONS
19	Radiation pneumonitis in pediatric Hodgkin lymphoma patients receiving radiation therapy to the chest. Practical Radiation Oncology, 2018, 8, e364-e368.	2.1	10
20	Incidence and predictors of treatmentâ€related conjugated hyperbilirubinemia during early treatment phases for children with acute lymphoblastic leukemia. Pediatric Blood and Cancer, 2020, 67, e28063.	1.5	9
21	Measuring relative telomere length: Is tissue an issue?. Aging, 2010, 2, 756-757.	3.1	9
22	DNA methylation and obesity in survivors of pediatric acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study. Genes Chromosomes and Cancer, 2019, 58, 52-59.	2.8	8
23	Hispanic ethnicity is associated with prolonged clearance of high dose methotrexate and severe nephrotoxicity in children and adolescents with acute lymphoblastic leukemia. Leukemia and Lymphoma, 2020, 61, 2771-2774.	1.3	8
24	Telomere Length-Associated Genetic Variants and the Risk of Thyroid Cancer in Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study (CCSS). Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 417-419.	2.5	7
25	Identifying patient―and familyâ€centered outcomes relevant to inpatient versus atâ€home management of neutropenia in children with acute myeloid leukemia. Pediatric Blood and Cancer, 2018, 65, e26927.	1.5	6
26	Evidence for Genetic Risk Contributing to Long-Term Adverse Treatment Effects in Childhood Cancer Survivors. Annual Review of Medicine, 2018, 69, 247-262.	12.2	6
27	Defining the Inflammatory Plasma Proteome in Pediatric Hodgkin Lymphoma. Cancers, 2020, 12, 3603.	3.7	6
28	Medical Outcomes, Quality of Life, and Family Perceptions for Outpatient vs Inpatient Neutropenia Management After Chemotherapy for Pediatric Acute Myeloid Leukemia. JAMA Network Open, 2021, 4, e2128385.	5.9	6
29	A report from the Leukemia Electronic Abstraction of Records Network on risk of hepatotoxicity during pediatric acute lymphoblastic leukemia treatment. Haematologica, 2022, 107, 1185-1188.	3.5	6
30	Clinical and functional characterization of telomerase variants in patients with pediatric acute myeloid leukemia/myelodysplastic syndrome. Leukemia, 2021, 35, 269-273.	7.2	4
31	Recommendations for Broader Coverage Antifungal Prophylaxis in Childhood Acute Myeloid Leukemia: ASH Evidence-Based Review 2011. Hematology American Society of Hematology Education Program, 2011, 2011, 374-376.	2.5	3
32	Monozygotic twins with non-Down syndrome associated <i>MLL</i> -rearranged hematologic malignancy and megakaryoblastic differentiation. Leukemia and Lymphoma, 2019, 60, 1083-1086.	1.3	3
33	Increased Disease Burden Among Black Children Compared to White Children with Newly Diagnosed Acute Myeloid Leukemia. Blood, 2018, 132, 369-369.	1.4	3
34	Sensor-based frailty assessment in survivors of childhood cancer: A pilot study. Journal of Frailty & Lamp; Aging, the, 2021, 10, 1-6.	1.3	3
35	Short NK- and $Na\tilde{A}$ -ve T-Cell Telomere Length Is Associated with Thyroid Cancer in Childhood Cancer Survivors: A Report from the Childhood Cancer Survivor Study. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 453-460.	2.5	3
36	Poorer Relapse-Free Survival in Hispanic Children Diagnosed with Acute Myeloid Leukemia Compared with Non-Hispanics: A Texas Single Institution Experience. Blood, 2015, 126, 1312-1312.	1.4	2

#	Article	IF	Citations
37	Distribution and frequency of tyrosine kinase inhibitorâ€associated longâ€term complications in children with chronic myeloid leukemia. Pediatric Blood and Cancer, 2022, 69, e29786.	1.5	2
38	Reply to "Peripheral blood lymphocyte recovery and overall survival in pediatric acute lymphoblastic leukemia― Pediatric Blood and Cancer, 2014, 61, 180-180.	1.5	1
39	Identifying relapses and stem cell transplants in pediatric acute lymphoblastic leukemia using administrative data: Capturing national outcomes irrespective of trial enrollment. Pediatric Blood and Cancer, 2021, 68, e28315.	1.5	1
40	A Targeted Next-Generation Sequencing Mutation Panel for Pediatric Acute Myeloid Leukemia and Myelodysplastic Syndrome (MDS) Detects Potential Additional Driver Mutations in Pediatric GATA2-MDS. Blood, 2015, 126, 1679-1679.	1.4	1
41	GATA2 Mutations In Nonsyndromic Pediatric Myelodysplastic Syndrome. Blood, 2013, 122, 2778-2778.	1.4	1
42	Risk of bacterial bloodstream infection does not vary by central-line type during neutropenic periods in pediatric acute myeloid leukemia. Infection Control and Hospital Epidemiology, 2023, 44, 222-229.	1.8	1
43	Epidemiology, Management and Outcome of Invasive Mold Infections Among Pediatric Hematological Malignancies at a Tertiary Care Center: A 10-Year Review. Open Forum Infectious Diseases, 2016, 3, .	0.9	O
44	Early evidence of pulmonary dysfunction in survivors of childhood Hodgkin lymphoma. Leukemia and Lymphoma, 2020, 61, 2419-2427.	1.3	0
45	Genetic and treatment risks for diabetes mellitus (DM) in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS) and St. Jude Lifetime (SJLIFE) cohorts Journal of Clinical Oncology, 2021, 39, 10014-10014.	1.6	O
46	An evidenceâ€based, riskâ€adapted algorithm for antifungal prophylaxis reduces risk for invasive mold infections in children with hematologic malignancies. Pediatric Blood and Cancer, 2021, 68, e29228.	1.5	О
47	Absolute Lymphocyte Counts Refine MRD-Based Risk Stratification in Pediatric ALL Blood, 2009, 114, 1593-1593.	1.4	O
48	Clinical and Molecular Characterization of Germline Telomerase Reverse Transcriptase (TERT) Variants in Children with Acute Myeloid Leukemia (AML),. Blood, 2011, 118, 3571-3571.	1.4	0
49	Constitutional Telomerase-Associated Gene Variants In Pediatric Acute Myeloid Leukemia (AML) and In Association With Chemotherapy-Related Toxicities. Blood, 2013, 122, 1310-1310.	1.4	O
50	Abstract 01: Genetic variation within genes related to telomere maintenance and DNA repair in a cohort of pediatric acute myeloid leukemia (AML) subjects. , 2014, , .		0
51	Risk for pulmonary late effects in childhood Hodgkin lymphoma survivors Journal of Clinical Oncology, 2017, 35, 112-112.	1.6	O
52	Using Administrative Data to Identify Relapse and Hematopoietic Stem Cell Transplantation (HSCT) in Children with Acute Lymphoblastic Leukemia (ALL): Validation at Two Centers and Incidence Estimation in a National Cohort. Blood, 2018, 132, 624-624.	1.4	0
53	Comparing the Liver Function of Children with Acute Lymphoblastic Leukemia (ALL) Receiving Standard or High Intensity Treatment during the Interim Maintenance I Phase of Therapy: A Study of 658 Patients. Blood, 2018, 132, 1383-1383.	1.4	O
54	Frailty among childhood cancer survivors: A report from the Childhood Cancer Survivor Study (CCSS) Journal of Clinical Oncology, 2019, 37, 10026-10026.	1.6	0

#	Article	IF	CITATIONS
55	Title is missing!. , 2020, 15, e0228887.		o
56	Title is missing!. , 2020, 15, e0228887.		O
57	Title is missing!. , 2020, 15, e0228887.		О
58	Title is missing!. , 2020, 15, e0228887.		0
59	Title is missing!. , 2020, 15, e0239040.		O
60	Title is missing!. , 2020, 15, e0239040.		0
61	Title is missing!. , 2020, 15, e0239040.		О
62	Title is missing!. , 2020, 15, e0239040.		0
63	Title is missing!. , 2020, 15, e0239040.		O
64	Title is missing!. , 2020, 15, e0239040.		0